Deutsche Bank Aktiengesellschaft Has Lowered Expectations for Spire Healthcare Group (LON:SPI) Stock Price

Spire Healthcare Group (LON:SPI) had its price target reduced by equities research analysts at Deutsche Bank Aktiengesellschaft from GBX 320 ($4.14) to GBX 300 ($3.88) in a research note issued on Thursday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price points to a potential upside of 69.30% from the company’s previous close.

Spire Healthcare Group Stock Down 6.0 %

LON SPI opened at GBX 177.20 ($2.29) on Thursday. The company has a debt-to-equity ratio of 62.25, a quick ratio of 0.74 and a current ratio of 0.70. The firm has a 50-day simple moving average of GBX 227.28 and a 200 day simple moving average of GBX 229.74. Spire Healthcare Group has a twelve month low of GBX 168.20 ($2.17) and a twelve month high of GBX 270.50 ($3.50). The stock has a market cap of £711.58 million, a PE ratio of 25.22, a PEG ratio of 1.06 and a beta of 0.96.

Spire Healthcare Group (LON:SPI) last released its earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) earnings per share for the quarter. Spire Healthcare Group had a net margin of 1.96% and a return on equity of 3.82%. On average, research analysts forecast that Spire Healthcare Group will post 15.6634747 EPS for the current year.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.